(Q38118900)

29 August 2017

title

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor (English)

1 reference

29 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Marian Iwamoto

1

1 reference

29 August 2017

Evan J Friedman

2

1 reference

29 August 2017

Punam Sandhu

3

1 reference

29 August 2017

Nancy G B Agrawal

4

1 reference

29 August 2017

Eric H Rubin

5

1 reference

29 August 2017

John A Wagner

6

1 reference

29 August 2017

publication date

3 July 2013

1 reference

Cancer Chemotherapy and Pharmacology

29 August 2017

published in

1 reference

29 August 2017

volume

72

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

493-508

1 reference

Histone deacetylases and cancer: causes and therapies

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Drug interactions in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

HDAC6 is a microtubule-associated deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

The pharmacology and pharmacokinetics of the retinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

Clinically relevant drug interactions with antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2220-Z

10.1007/S00280-013-2220-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1041009341

0 references

1 reference